康柏西普联合激光治疗急进性早产儿视网膜病变

doi:10.6040/j.issn.1673-3770.0.2018.272

摘要/Abstract

摘要： 目的观察康柏西普、激光单独及联合治疗急进性早产儿视网膜病变(ROP)的临床效果。方法采用等距随机抽样法将2016年2月至2017年12月收治的63例(126眼)ROP患儿随机分为激光治疗组、康柏西普治疗组、康柏西普联合激光治疗组,每组21例(42眼)。对比3组临床疗效,观察视网膜电流图相关分析指标及等效球镜度、散光度数变化,并分析治疗期间并发症发生情况及随访结果。结果激光治疗组、康柏西普治疗组、康柏西普联合激光治疗组患者疾病控制率分别为71.43%、66.67%、95.24%(H=5.694, P=0.058)。在闪光视网膜电图(F-ERG)反应振幅上,视杆反应b波、最大混合反应a、b波,3组比较差异均有统计学意义(P均<0.05)。在F-ERG反应潜伏期,视锥反应a、b波,3组比较差异均有统计学意义(P均<0.05)。3组患者近视、高度近视、散光、高度散光发生率比较,差异均有统计学意义(P均<0.05)。激光治疗组、康柏西普治疗组、康柏西普联合激光治疗组患者并发症发生率分别为23.80%、19.04%、14.28%(χ2=0.618, P=0.432)。随访期间,激光治疗组、康柏西普治疗组、康柏西普联合激光治疗组患者ROP复发率为33.33%、28.57%、4.76%,激光治疗组、康柏西普治疗组ROP复发率均高于康柏西普联合激光治疗组(P均<0.05)。结论康柏西普联合激光治疗ROP临床疗效较好,安全性较高。

关键词: 康柏西普, 激光, 急进性, 早产儿, 视网膜病变

Abstract: Objective To observe the clinical effect of treatment with Compaq, laser, and a combination for the treatment of retinopathy of prematurity(ROP). Methods Sixty-three children(126 eyes)with ROP treated in our hospital from February 2016 to December 2017 were randomly divided into three groups of 21 patients(42 eyes)using the envelope method. Laser photocoagulation treatment group was treated with laser photocoagulation alone, compaq treatment group was treated with compaitcept glass cavity injection alone, and combined treatment group was treated with compaitcept glass body cavity injection and laser irradiation combined with laser photocoagulation. The clinical effects observed in the three groups were compared, and the indices related to the retinal electroretinogram and changes in the equivalent spherical mirror and astigmatism were analyzed. Complications and follow-up results were analyzed during and after treatment. Results The rate of controlled disease in laser photocoagulation treatment group, compaq treatment group and combined treatment group was 71.43%, 66.67% and 95.24%(H=5.694, P=0.058). Regarding the amplitude of the flash electroretinogram(F-ERG)reaction, the amplitude of the b-wave, the cone-rod mixed maximum response a- and b-waves, there was significant difference between the above three groups(all P<0.05). Regarding the F-ERG response latency, peak mixed rod-cone response a- and b-wave, there was significant difference between the above three groups(all P<0.05). Regarding myopia, high myopia, astigmatism, and high astigmatism, there was significant difference between the above three groups(all P<0.05). The incidence of complications was 23.80%, 19.04% and 14.28%(χ2=0.618, P=0.432)in laser photocoagulation treatment group, compaq treatment group and combined treatment group. During the follow-up period, the recurrence rate of ROP in laser photocoagulation treatment group, compaq treatment group and combined treatment group was 33.33%、28.57% and 4.76%. The recurrence rate of ROP in laser photocoagulation treatment group and compaq treatment group significantly higher than that in combined treatment group(all P<0.05). Conclusion Treatment with Compaq combined with laser is effective and safe for the treatment of ROP.

Key words: Compaq, laser, Rapid advance, Premature, Retinopathy of prematurity

中图分类号:

R779.7

郭宝,张德勇. 康柏西普联合激光治疗急进性早产儿视网膜病变[J]. 山东大学耳鼻喉眼学报, 2018, 32(6): 92-97.

GUO Bao, ZHANG Deyong. Clinical study of compaq combined with laser in the treatment of retinopathy of prematurity[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2018, 32(6): 92-97.

参考文献

[1] Fang JL, Sorita A, Carey WA, et al. Interventions to prevent retinopathy of prematurity: a meta-analysis[J]. Pediatrics, 2016, 137(4):1-17.
[2] Yum SK, Moon CJ, Youn YA, et al. Expanded criteria for retinopathy of prematurity screening in moderately preterm infants: Single-center pilot study[J]. Ped Inter, 2016, 58(11):1158-1162.
[3] Lok JYC, Yip WWK, Luk ASW, et al. Visual outcome and refractive status in first 3 years of age in preterm infants suffered from laser-treated Type 1 retinopathy of prematurity(ROP): a 6-year retrospective review in a tertiary centre in Hong Kong[J]. Inter Ophthalmol, 2018, 38(1):163-169.
[4] 程湧, 梁建宏, 黎晓新. 康柏西普玻璃体腔注射治疗急进性后极部早产儿视网膜病变的疗效观察[J]. 中华眼底病杂志, 2017, 33(2):144-147. CHENG Yong, LIANG Jianhong, LI Xiaoxin, et al. Intravitreal injection of conbercept for aggressive posterior retinopathy of prematurity[J]. Chin J Ocular Fundus Dis, 2017, 33(2):144-147.
[5] 中华医学会眼科学分会眼底病学组. 中国早产儿视网膜病变筛查指南(2014年)[J]. 中华眼科杂志, 2014, 50(12):933-935.
[6] Visser L, Singh R, Young M, et al. Guideline for the prevention, screening and treatment of retinopathy of prematurity(ROP)[J]. S Afr Med J, 2012, 103(2):116-125.
[7] 刘海洋, 李盨雁, 张正培,等. 改良膜分割与双手膜清除技术在23 G玻璃体手术治疗增殖性糖尿病视网膜病变中的对比[J].山东大学耳鼻喉眼学报, 2015, 29(1):52-55. LIU Haiyang, LI Suyan, ZHANG Zhengpei, et al. Comparison of improved membrane dissection and bimanual enbloc excision in 23 G vitrectomy to treat prolifera-tive diabetic retinopathy[J]. J Otolaryngol Ophthalmol Shandong Univ, 2015, 29(1):52-55.
[8] 周学义, 李一鸣, 王美菊,等. 25+微创玻璃体视网膜手术联合玻璃体腔注射雷珠单抗治疗增生型糖尿病视网膜病变的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(4):87-89. ZHOU Xueyi, LI Yiming, WANG Meiju, et al. The application of 25-gauge minimally invasive vitreoretinal surgery combined with intravitreal ranibizumab in jections in the treatment of proliferative diabetic retinopathy[J]. J Otolaryngol Ophthalmol Shandong Univ, 2017, 31(4):87-89.
[9] Kabata EU, Kurtul BE, Özer P A, et al. Comparison of intravitreal bevacizumab, intravitreal ranibizumab and laser photocoagulation for treatment of type 1 retinopathy of prematurity in turkish preterm children[J]. Curr Eye Res, 2017, 42(7):1054-1058.
[10] Hondur AM, Çubuk MÖ, Özen Tunay Z, et al. Intravitreal bevacizumab for retinopathy of prematurity in infants ineligible for laser therapy[J]. Turk J Med Sci, 2016, 46(3):764-768.
[11] 焦明菲, 李筱荣. 康柏西普玻璃体腔注射治疗高度近视脉络膜新生血管的临床疗效及安全性分析[J]. 中华实验眼科杂志, 2016, 34(8):725-728. JIAO Mingfei, LI Xiaorong. Clinical safety and efficacy of conbercept intravitreal injection on high myopic choroidal neovascularization[J]. Chin J Exp Ophthalmol, 2016, 34(8):725-728.
[12] 刘三梅, 李杰, 董文韬,等. 玻璃体腔内注射康柏西普联合视网膜光凝治疗增生性糖尿病视网膜病变的中长期临床观察[J]. 成都中医药大学学报, 2017, 40(1):63-65. LIU Sanmei, LI Jie, DONG Wentao, et al. Long-term clinical observation of intravitreal injection of conbercept combined with pan retinal photocoagulation in the treatment of patients with proliferative diabetic retinopathy[J]. J Chengdu Univ Trad Chin Med, 2017, 40(1):63-65.
[13] 姚昱欧, 尹虹, 黎晓新,等. 激光光凝治疗对早产儿视网膜病变视野及屈光状态的影响[J]. 中华眼底病杂志, 2017, 33(2):148-152. YAO Yuou, YIN Hong, LI Xiaoxin Zhao, et al. Visual field outcomes and refractive status of retinopathy of prematurity after laser treatment[J]. Chin J Ocular Fundus Dis, 2017, 33(2):148-152.
[14] 罗毅, 王平. 早产儿视网膜病变的神经视网膜发育研究[J]. 国际眼科杂志, 2015, 15(10):1741-1744. LUO Yi, WANG Ping. Development of neural retina in retinopathy of prematurity[J]. Inter Eye Sci, 2015, 15(10):1741-1744.
[15] 黄江, 易全勇, 季晓燕,等. 急性中心性浆液性脉络膜视网膜病变激光治疗前后渗漏灶视网膜色素上皮形态变化观察[J]. 中华眼底病杂志, 2016, 32(3):266-269. HUANG Jiang, YI Quanyong, JI Xiaoyan, et al. Morphologic features of retina pigment epithelial around fluorescein leakage sites in acute central serous chorioretinopathy before and after laser coagulation[J]. Chin J Ocular Fundus Dis, 2016, 32(3):266-269.
[16] 韩林峰, 柯根杰, 王林,等.全视网膜激光光凝对增生型糖尿病视网膜病变视网膜前膜中环氧化酶-2、血管内皮生长因子表达的影响[J]. 中华眼底病杂志, 2016, 32(2):140-143. HAN Linfeng, KE Genjie, WANG Lin, et al. Effect of panretinal photocoagulation on the expression of cyclooxygenase-2, vascular endothelial cell growth factor in epiretinal membrane of proliferative diabetic retinopathy[J]. Chin J Ocular Fundus Dis, 2016, 32(2):140-143.
[17] 田汝银, 张国明, 程璐璐,等. 早产儿视网膜病变激光术后嵴前无血管区的临床观察[J]. 国际眼科杂志, 2017, 17(4):778-780. TIAN Ruyin, ZHANG Guoming, CHENG Lulu, et al. Clinical outcome of nonvascularization area after laser photocoagulation in patients with retinopathy of prematurity[J]. Inter Eye Sci, 2017, 17(4):778-780.
[18] 赵旭丽, 张娣, 阳光,等. 术前玻璃体腔注射康柏西普对严重增生型糖尿病视网膜病变手术的影响[J]. 中国眼耳鼻喉科杂志, 2018, 18(1):22-25. ZHAO Xuli, ZHANG Di, YANG Guang, et al. Intravitreal conbercept as a pretreatment of vitrectomy for patients with severe proliferative diabetic retinopathy[J]. Chin J Ophthalmol Otorhinolaryngol, 2018, 18(1):22-25.
[19] 张艳, 柴剑. 激光联合康柏西普治疗对糖尿病性视网膜病变患者血清细胞因子及氧化产物的影响[J]. 海南医学院学报, 2017, 23(11):1586-1588. ZHANG Yan, CHAI Jian. Influence of Laser combined with Conbercept on serum cytokines and oxidation products in diabetic retinopathy patients[J]. J Hainan Med Univ, 2017, 23(11):1586-1588.

相关文章 15

[1]	赵娟,焦万珍,赵博军. UWFSS-OCTA检测糖尿病视网膜病变微循环的变化[J]. 山东大学耳鼻喉眼学报, 2026, 40(2): 80-86.
[2]	孙庆祝,沈健,陈星,吴雁冰,曾论. 代谢指标在预测糖尿病性黄斑水肿患者雷珠单抗疗效中的作用[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 74-81.
[3]	朱云龙,王平,高萌. 误诊为中浆及视网膜炎的后巩膜炎1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 99-105.
[4]	高琳,何金梅,杨明祎. 糖尿病视网膜病变患者血清Sestrin2和NADPH氧化酶2水平与眼底病变的相关性[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 113-117.
[5]	宋艳玲,司元元,崔彦. 微量玻璃体切除治疗激光笔致儿童全层黄斑裂孔1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 144-147.
[6]	陈涛,姜洋,李莹. SMILE矫正PRK术后屈光回退1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 148-153.
[7]	张国明,魏文斌,林浩添,迟玮,张少冲,赵培泉,雷柏英,陈有信,王雨生,何明光,梁建宏,卢海,陆方,黄欣,梁小玲,赵欣予,吴桢泉,余震,崔凯璇,刘亚玲,项道满,陈长征,张自峰,林铎儒,于珊珊,孙悦,檀韬,陈燕先,彭婕,董力,程湧,朱雪梅,杨鹏,陈少滨. 人工智能技术辅助早产儿视网膜病变诊疗专家共识(2025)[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 1-5.
[8]	王坛,王晶,李燕子,卜苓南,杨淑娟. 下咽纤维血管性息肉1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 121-125.
[9]	肖哲,张胜娟,赵子琦,兴辰,李成泉,刘志强. Ultra Q:YAG激光治疗黄斑部视网膜前出血17例并文献复习[J]. 山东大学耳鼻喉眼学报, 2025, 39(1): 130-135.
[10]	杜一帆,齐林嵩,李莹. 飞秒激光小切口角膜基质透镜取出术对眼高阶像差影响的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(1): 152-161.
[11]	杨淞月,张美霞. 单细胞RNA测序技术在视网膜中的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(1): 162-170.
[12]	辛梦,纪芳,代春华,张靖,刘澍. 医用透明质酸钠与平衡盐溶液在微创玻璃体手术中对眼表保护的影响[J]. 山东大学耳鼻喉眼学报, 2024, 38(5): 58-65.
[13]	常威威,焦万珍,崔艳艳,赵杰,刘兆强,赵博军. 糖尿病性黄斑缺血的研究进展[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 130-136.
[14]	胡亚柔,赵欣予,吴桢泉,范梓欣,余震,刘亚玲,陈婷毅,曾键,张国明. 早产儿屈光状态与眼部生物特征的研究进展[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 144-150.
[15]	周静琳,李金香,曾琦. 577 nm阈值下微脉冲激光联合抗VEGF药物治疗难治性糖尿病性黄斑水肿的疗效观察[J]. 山东大学耳鼻喉眼学报, 2024, 38(2): 18-25.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed